Urorec Added to Repatriation Schedule of Pharmaceutical Benefits

Urorec® (silodosin) was recently approved for reimbursement on the Repatriation Schedule of Pharmaceutical Benefits (RPBS) effective 1 July 2020 and is indicated for the relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men. Urorec® will be RPBS authority listed for Benign Prostatic Hyperplasia with the clinical criteria that the patient must have lower urinary tract symptoms.

The item numbers below include links to the schedule:

• 12079R SILODOSIN, silodosin 4 mg capsule, 30 (Urorec)
• 12077P SILODOSIN, silodosin 8 mg capsule, 30 (Urorec)
   

Access full listing details and a summary of changes on the Department of Health website.
Access further information about Urorec on the maynepharma website.